Cherry SE (ETR:C3RY)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.81M -45.8% |
| Revenue (ttm) | 96.91M -20.6% |
| Net Income | -52.02M |
| EPS | -2.23 |
| Shares Out | 23.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,105 |
| Average Volume | 25,304 |
| Open | 0.4800 |
| Previous Close | 0.4660 |
| Day's Range | 0.4660 - 0.4800 |
| 52-Week Range | 0.3800 - 1.1000 |
| Beta | 0.98 |
| RSI | 48.61 |
| Earnings Date | May 7, 2026 |
About Cherry SE
Cherry SE, together with its subsidiaries, manufactures and sells computer input devices in Germany. The company offers keyboards, mice, desktop sets, headsets, microphones, keyboard and desktop switches, and terminals; accessories, such as covers and mouse; and software and related services. It also provides e-health terminals and PIN pads for the healthcare sector. The company serves office and home office, gaming, healthcare, security, POS, and IOT sectors. It sells its products through distributors, resellers, system houses, retailers, and ... [Read more]
Financial Performance
In 2024, Cherry SE's revenue was 110.45 million, a decrease of -12.66% compared to the previous year's 126.46 million. Losses were -45.45 million, -64.18% less than in 2023.
Financial StatementsNews
Cherry SE Earnings Call Transcript: Q4 2025
2025 saw a major operational cleanup, cost reductions, and a focus on core segments, with revenue down 15% but like-for-like growth of 4.7%. Digital Health is shifting to a platform model, Peripherals margins are recovering, and an M&A process is underway for a segment divestment.
Cherry SE Earnings Call Transcript: Q2 2025
Revenue declined 25% YoY to €46M in H1 2025, with adjusted EBITDA margin at -5% due to restructuring and weak demand. Liquidity improved via inventory reduction and the sale of the hygiene business, while digital health is positioned for growth amid regulatory tailwinds.
Cherry SE Transcript: Analyst Day 2025
Restructuring includes shifting switch production to China, major SKU reduction, and a new focus on high-margin peripherals and digital health. 2025 guidance targets EUR 105–120 million revenue and 3–6% EBITDA margin, with margin recovery expected in H2.
Cherry SE Earnings Call Transcript: Q4 2024
2024 revenue fell short of forecasts due to weak Americas and switch business, but digital health saw strong growth and cost controls led to positive Q4 free cash flow. Strategic restructuring and new partner programs aim to drive recovery, with a focus on returning to profitability in 2025.
Cherry SE Earnings Call Transcript: Q3 2024
Q3 2024 saw a sharp revenue and EBITDA decline, mainly due to weak German demand and internal issues, prompting restructuring and cost-cutting. Digital Health showed strong growth, while Gaming and Office Peripherals and Components lagged. Full-year guidance was lowered.
Cherry SE Earnings Call Transcript: Q2 2024
H1 2024 saw modest sales growth and a significant margin improvement, driven by Digital Health and Solutions, while cost controls and restructuring advanced ahead of plan. Full-year guidance is maintained despite macroeconomic and logistical risks, with Q4 expected to deliver strong seasonal results.